Senores Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2026, Senores Pharmaceuticals (SENORES) reported revenue ₹193 Cr and net profit ₹37 Cr — revenue +53.2% YoY. Also explore Senores Pharmaceuticals stock price data download to track price trends across different timeframes.
SENORES Quarterly Results — Revenue, Profit & EPS Highlights
Senores Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Browse SENORES complete financial statements for revenue, profit, balance sheet and cash flow data.
- Revenue of ₹193 Cr in Mar 2026 (+21.4% vs Sept 2025, +53.2% vs Mar 2025)
- Net Profit of ₹37 Cr in Mar 2026 (+23.3% vs Sept 2025, +105.6% vs Mar 2025)
- EBITDA of ₹65 Cr in Mar 2026 (+38.3% vs Sept 2025)
- Operating Margin of 27.0% in Mar 2026 (+0.0pp vs Sept 2025)
- Earnings Per Share of ₹7.96 in Mar 2026 (+21.7% vs Sept 2025)
Senores Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SENORES quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 193 | 159 | 126 | 134 | 178 | 21.4% | 53.2% |
| Net Profit (₹ Cr) | 37 | 30 | 18 | 21 | 34 | - | - |
| EBITDA (₹ Cr) | 65 | 47 | 31 | 30 | 58 | - | - |
| EPS (₹) | 7.96 | 6.54 | 3.81 | 4.60 | 7.29 | - | - |
| Operating Margin (%) | 27.0% | 27.0% | 17.0% | 20.0% | 29.0% | - | - |
SENORES Share Price Trend — 1-Year Movement Across Quarterly Results
Senores Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Senores Pharmaceuticals stock price NSE.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SENORES vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Senores Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹454,122.13 Cr | 1904.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 168.6 |
|
Divis Laboratories
Mar 2026 |
₹174,081.02 Cr | 6757.0 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 238.7 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹161,380.94 Cr | 4768.3 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.3 |
|
Cipla
Mar 2026 |
₹117,800.00 Cr | 1458.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 212.3 |
|
Dr Reddys Laborator…
Mar 2026 |
₹114,691.88 Cr | 1374.1 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 518.5 |
All amounts in ₹ Crores